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Abstract
Background: Urotensin-II (U-II) is a peptide recognized by its potent vasoconstrictor activity in many vascular
events, however the role of urotensin-II in migraine has not been considered yet. The molecular mechanisms and
genetics of migraine have not been fully clarified yet, but it is well-known that vascular changes considerably
contribute in pathophysiology of migraine and also its complications. The aim of this study was to analyze the
plasma U-II levels along with genotype distributions and allele frequencies for UTS2 Thr21Met and Ser89Asn
polymorphisms among the patients with migraine without aura (MWoA).
Methods: One hundred eighty-six patients with MWoA and 171 healthy individuals were included in this study.
Plasma U-II levels were measured in attack free period. The genotype and allele frequencies for the Thr21Met
(T21M) and Ser89Asn (S89N) polymorphisms in the UTS2 gene were analyzed.
Results: Plasma U-II levels were significantly higher in MWoA patients (p = 0.002). We detected a significant
association between the T21M polymorphism in the UTS2 gene and migraine (53.8 % in patients, 40.4 % in
controls, p = 0.035), but not with S89N polymorphism (p = 0.620). A significant relationship was found between U-II
levels and MIDAS score (β = 0.508, p = 0.001).
Conclusion: Our study suggests that U-II may play a role in migraine pathogenesis; also Thr21Met polymorphism
was associated with the risk of migraine disease. Further studies are needed for considering the role of U-II in
migraine pathophysiology and for deciding if UTS2 gene may be a novel candidate gene in migraine cases.
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Background
Migraine is a common neurological disorder that affects
approximately 12 % of the population [1]. However, in
recent years, it has been suggested that migraines are
formed as a result of neuronal vascular event chains trig-
gered by endogenous and/or exogenous factors in people
with a genetic predisposition [2, 3]. Many first-degree
relatives of migraine patients have a history of migraines,
and twin studies conducted show that migraines have a
strong genetic component [4–6].
Urotensin-2 (U-II) is a cyclic peptide composed of 11
amino acids that was first isolated from the goby neurose-
cretory system in 1969 [7]. The human receptor for U-II
(hUT2R) is a G-protein coupled receptor (GPR14) [8]. U-II
and its receptor (UTR) are found in different tissues such
as the central nervous system, peripheral vascular tissues,
the heart, and the kidneys [8, 9]. Clark et al. suggested that
UII receptor mRNA and choline acetyltransferase exist to-
gether in the mesopontine tegmental area [10]. U-II is a
vasoactive substance that has a similar peptide structure to
somatostatin and is a more powerful vasoconstrictor than
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endothelin-1 (ET-1) [11]. The vasoconstrictor effect of U-II
is 50 times higher on arteries and 10 times higher on veins
than ET-1. U-II is thought to have endothelium-dependent
vasodilator and endothelium-independent vasoconstrictor
effects, and its net effect may depend on the balance be-
tween these two individual effects [12]. However, studies
have shown that it plays other physiological roles beyond
the regulation of vascular tone and cholinergic activity. The
urotensinergic system has been shown to be associated with
heart failure, hypertension, diabetes, preeclampsia, renal
and liver diseases, neurological and psychiatric disorders
[13, 14]. U-II is known to be expressed in the brain and
spinal cord. It is recognized as a neuro-mediator in the cen-
tral nervous system [15, 16].
U-II may also play a role in migraine pathogenesis,
especially considering its known effects on the central
and peripheral nervous system. The U-II gene (UTS2) is
located at the 1p36 locus. According to data from the
US National Center for Biotechnology Information,
more than 60 single nucleotide polymorphisms (SNPs)
have been recorded in the human UTS2 gene. Thr21Met
(T21M, rs228648) and Ser89Asn (S89N, rs2890565)
polymorphisms have been found at high allelic frequen-
cies in Japanese populations [17]; these are the same
polymorphisms that were selected for investigation in
our study. Although many studies have shown the roles
of various genetic factors and polymorphisms in mi-
graine disease, no studies have focused on theT21M and
S89N polymorphisms in the UTS2 gene in migraine
patients until now.
Therefore, the purpose of this study is to examine the
possible relationships between the T21M and S89N
polymorphisms in the UTS2 gene and MWoA and to
detect the possible role of U-II in the pathogenesis of
MWoA by measuring serum U-II levels.
Methods
Study population
Study approval was obtained from the Ethics Committee
of the Gaziantep University Faculty of Medicine. Informed
consent was obtained from all subjects prior to the study.
This study examined 186 consecutive patients aged 18–
45 years, who were diagnosed as having migraines, had
not been on prophylactic treatment for at least 3 months
and had least 72 h migraine attack drug-free period before
obtaining blood samples in the interictal phase. Since it is
thought to have endothelium-dependent vasodilator and
endothelium-independent vasoconstrictor effects, and its
net effect may depend on the balance between these two
individual effects and we don’t know if it has an effect in
migraine attacks we decided to obtain the blood samples
in the interictal phase from all of the patients.
Migraines were diagnosed according to the ICHD-2
criteria [18] by experienced neurologists in our clinic
and then enrolled into the study. For homogenizing the
group, we selected only MWoA patients. The control
group (n = 171) was composed of age and gender matched
healthy cases that consented to join to the control group.
Cases with history of diabetes mellitus (fasting blood
glucose ≥ 120 mg/dl); hypertension (Blood pressure (BP) ≥
140/90 mmHg); chronic renal failure; liver cirrhosis; any
type of cancer; thyroid diseases; alcohol and substance
abuse; chronic neurologic illnesses, including epilepsy,
Parkinson’s disease, Huntington’s disease, Alzheimer’s dis-
ease, Wilson’s disease, and previous cerebrovascular and
cardiovascular diseases, morbid obesity; and any existing
infection were excluded from both groups. The medical
histories, physical and neurologic examination findings, and
body mass indices (BMI) of all cases were recorded. The
migraine patients were questioned regarding the disease
duration, the type of migraine, the frequency of migraine
attacks (for the last 3 months), drugs used, and smoking.
The Migraine Disability Assessment Scale (MIDAS) was
applied to measure the extent to which migraine headaches
decreased the patients’ standard of living. Routine labora-
tory examinations, including total blood count, serum elec-
trolytes, serum creatinine, blood urea nitrogen (BUN),
fasting blood glucose levels, and liver function tests, were
performed in all cases. The glomerular filtration rate (GFR)
was calculated according to the Modification of Diet in
Renal Disease (MDRD) guidelines [19].
Power analysis
Sample size was estimated using a power calculation
based on 0.2 ± 0.6 changes in urotensin between groups. It
was estimated that at least 142 participants in each group
would be required to detect a significant difference be-
tween control and migraine groups at 80 % power level
and an alpha error of % 5.
Blood samples and DNA isolation
Venous blood samples were drawn from the antecubital
vein in the morning hours after 12 h of fasting and for
at least 72 h without symptomatic migraine medication.
The plasma was separated from the blood samples by
adding EDTA and centrifuging the samples at 1000 g for
15 min. The plasma samples were then stored at -80 °C
until U-II levels were measured. Plasma U-II concentra-
tions were measured using a quantitative sandwich-type
enzyme immunoassay UT2 kit (Elx 800 ELISA; Cusabio
Biotech, Winooski, VT, USA). Genomic DNA extraction
was performed from the plasma-free blood pellets using
a standard proteinase K and salt precipitation method.
The extracted DNA was stored at -20 °C.
SNP genotyping
Samples were genotyped for the UTS2 SNPs using a vali-
dated TaqMan SNP Genotyping Assay (Applied Biosystems
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Inc. (ABI), Foster City, CA, USA) that employed prede-
signed primers and probes for the UTS2 gene SNPs
(T21M, rs228648; S89N, rs2890565) (ABI). One allelic Taq-
Man probe was labeled with a fluorescent FAM dye, and
the other was labeled with a VIC dye. For each polymerase
chain reaction (PCR), 5 μL of genomic DNA solution
(5 ng/μL) was added to an aliquot of 2× TaqMan universal
PCR Master Mix, resulting in primer and probe final
concentrations of 180 and 40 nM, respectively. The amplifi-
cation protocol consisted of the following steps: (1) an
initial denaturation at 95 °C for 10 min and (2) 40 cycles of
denaturation at 95 °C for 15 s and annealing and extension
at 60 °C for 1 min, with amplification and fluorescence de-
tection performed using a Qiagen Rotor-Gene Q Real-time
PCR system. At least 10 % of the blood samples were run
twice in separate assays with a concordance of genotype
designation of 100 %.
Statistical analysis
The results are expressed as either means ± the standard
deviations (SDs) or the percentage. Statistical analysis
was performed using the Statistical Package for Social
Sciences (SPSS) software version 20.0 (Inc. Chicago, IL).
The chi-squared test was used to calculate significant differ-
ences in the genotype and allele frequencies. The unpaired
Student’s t test was used to compare the differences be-
tween the mean values of the 2 groups. The effects of the
genetic polymorphisms on the risk of SSc were estimated
with an odds ratio (OR) and 95 % confidence interval (CI).
The haplotype analysis was performed using SHEsis soft-
ware (http://analysis.bio-x.cn/myAnalysis.php). All of the
statistical tests and p values were two-sided, and p < 0.05
was considered statistically significant.
Results
One hundred eighty-six patients diagnosed with MWoA
and 171 healthy control subjects were enrolled in this
study. No significant differences existed between the two
groups in terms of gender distribution, age, BMI, or
smoking status. A total of 101 (54.3 %) migraine patients
were using migraine attack drugs (triptans, nonsteroidal
anti-inflammatory drugs (NSAIDs), paracetamol and
combination analgesic). The demographic and laboratory
characteristics of the study group are shown in Table 1.
Plasma urotensin-2 levels by ELISA assay
The mean U-II levels were 1.19 ± 0.69 pg/ml in the mi-
graine group and 0.97 ± 0.7 pg/ml in the control group.
U-II plasma levels were significantly higher in the mi-
graine group (p = 0.002) (Fig. 1). No differences in U-II
levels were found in terms of gender, smoking status,
symptomatic medication history in either group (Table 2).
Disease duration and attack frequency were not signifi-
cantly correlated with U-II levels (β:0.48/p:0.657, β: 0.195/
p:0.175; respectively). A significant relationship was found
between U-II levels and MIDAS score. U-II levels were
significantly higher in patients with higher MIDAS scores.
A 1 unit increase in the MIDAS score resulted in a 0.508
unit increase in U-II levels (β = 0.508, p = 0.001) (Fig. 2).
Genotyping
Genotype and allele frequencies for T21M (rs228648)
and S89N (rs2890565) polymorphisms in the UTS2 gene
in the patient and control groups are shown in Table 3.
We detected a significant association between the T21M
polymorphism in the UTS2 gene and migraine but no
significant relationship between the S89N polymorphism
and migraine in our study (p = 0.620). T21T genotype
frequency was more prevalent in the control group
(34.4 % in the patients compared with 42.1 % in the
controls). T21M genotype frequency was more prevalent
in the migraine group (53.8 % in the patients compared
with 40.4 % in the controls, p = 0.035) and the According
to these results, patients with theT21M genotype are
1.63 times more likely to become migraine patients than
patients with the T21T genotype (OR = 1.63, p = 0.035).
Table 1 Demographic, clinical and laboratory characteristics of
the patient and control groups
Parameters Patients (n = 186) Control (n = 171) p
Mean age (years) 29.30 ± 5.45 28.77 ± 5.44 0.360
Gender (n, %)
Female 133 (71.5) 124 (72.5) 0.832
Male 53 (28.5) 47 (27.5)
BMI (kg/m2) 25.94 ± 2.84 26.02 ± 2.86 0.795
Hgb (g/dL) 12.68 ± 0.6 12.66 ± 0.6 0.538
Wbc (×103/mL) 5.9 ± 1.17 4.46 ± 1.17 0.190
Urea (mg/dL) 18.55 ± 4.91 18.60 ± 4.95 0.927
GFR (ml/min) 106 ± 7 101 ± 9 0.206
ESR (mm/h) 4.96 ± 1.44 4.97 ± 1.45 0.929
CRP (mg/L) 0.71 ± 0.3 0.7 ± 0.3 0.725
Smoking (n, %) 41 (22) 38 (22.2) 0.967
Disease duration (years) 6.98 ± 3.87
Attack frequency (n, %)
1–5/month 114 (61.3)
6–10/month 56 (30.1)
> 10/month 16 (8.6)
MIDAS score 2.86 ± 1.12
Vomiting 99 (52.3)
FF 143 (76.8)
Mood changes 132 (70.9)
BMI body mass index, ESR erythrocyte sedimentation rate, CRP C-reactive
protein, GFR glomerular, Hgb hemoglobin, WBC white blood cell
MIDAS Migraine Disability Assessment Scale, FF photophobia
and phonophobia
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No significant differences were found in the 21 M poly-
morphism allele frequencies between the migraine and
control groups (p = 0.786). Moreover, no significant rela-
tionships were found between the MIDAS scores and the
T21M (p = 0.502) or S89N (p = 0.300) polymorphisms in
the UTS2 gene in the migraine groups. Finally, no signifi-
cant relationships were found between the smoking status
and the T21M (p = 0.885) or S89N (p = 0791) polymor-
phisms in the UTS2 gene in the migraine group. There
were insignificant increases in MN, MS and TS haplotype
frequencies in migraine patients (Table 4).
Relationship between genotypes and expression
The plasma levels of U-II were tended to be higher without
statistical significance in TM and MM genotype (p = 0.545).
The relationship between plasma U-II protein level and
Thr21Met polymorphism in patients was shown in Fig. 3.
Discussion
Our results revealed a significant elevation of serum U-II
levels in migraine patients. Additionally, a significant
association of migraine with T21M polymorphism but not
with S89N polymorphism of urotensin gene was observed
in the present study.
Several peptides have been reported in relation with mi-
graine pathophysiology. The role of calcitonin gene-
related peptide (CGRP) in migraine pathogenesis is still
under investigation in current researches [20, 21]. Pituit-
ary adenylate cyclase-activating polypeptide and substance
P (SP) had craniocervical vasodilatation, plasma protein
Fig. 1 Urotensin-2 levels (pg/mL) in the migraine and control groups
Table 2 Comparison of plasma Urotensin-II levels according to




Migraine Control p value
Smoking 1.15 ± 0.51 0.99 ± 0.52 0.003*
Non-smoking 1.104 ± 0.6 0.82 ± 0.61 0.001*
p value 0.965 0.854
Female 1.19 ± 0.48 0.96 ± 0.62 0.001*
Male 0.98 ± 0.45 0.84 ± 0.48 0.003*
p value 0.185 0.832
Drugs (+) 1,13 ± 0.4 -
Drugs (–) 1,11 ± 0.51 -
p value 0,981
Vomiting (+) 1.21 ± 0.6
Vomiting (–) 1.04 ± 0.51
p value 0.004*
FF (+) 1.19 ± 0.5
FF (-) 1.17 ± 0.6
p value 0.967
Mood (+) 1.28 ± 0.7
Mood (-) 0.99 ± 0.6
p value 0.001*
Valuables are expressed as the mean ± SD
Drug (+): Using symtomatic migraine drugs
Drug (-): Not using symptomatic migraine drugs
FF photophobia and phonophobia
*p < 0.05
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extravasation, peripheral and central sensitization effects
in migraine pathogenesis [22]. Serum levels of vaso-
active intestinal peptide (VIP); a marker of parasympa-
thetic nervous system, was found to be increased in
chronic and episodic migraineurs in attack free period
[23]. Diverse results for neuropeptide Y (NPY); a marker
of sympathetic nervous system with long-lasting vaso-
constrictor effects in cerebral circulation, was reported in
migraineurs [22].
U-II and its receptor have many functions, including the
regulation of behavior and neuroendocrine activities,
cardiovascular tone control, motor activity, the sleep-wake
cycle, and hypothalamic-pituitary-adrenal axis control [14,
24–26]. U-II plasma concentrations are low in healthy indi-
viduals [13]. Previously some studies have measured higher
UT2 peptide levels in various metabolic and cardiovascular
diseases such as; chronic heart failure, acute myocardial
infarction, hypertension and diabetes mellitus [27–29].
Fig. 2 The correlation between U-II levels and MIDAS scores
Table 3 Distributions of the T21M and S89N polymorphisms among the groups
Genotype/Allele Control
(n = 171) n (%)
Migraine
(n = 186) n (%)
p OR [95 % CI]
T21M
TT 72 (42.1) 64 (34.4) Reference
TM 69 (40.4) 100 (53.8) 0.035 1.63 [1.034–2.571]
MM 30 (17.5) 22 (11.8) 0.559 0.825 [0.433–1.572]
T 213 (62.3) 228 (61.3) Reference
M 129 (37.7) 144 (38.7) 0.786 1.043 [0.771–1.411]
HWE p = 0.065 p = 0.069
S89N
SS 151 (88.3) 161 (86.6) Reference
SN 20 (11.7) 25 (13.4) 0.620 1.172 [0.625–2.198]
NN 0 (0.0) 0 (0.0) -
S 322 (94.2) 347 (93.3) 0.632 0.862 [0.470–1.582]
N 20 (5.8) 25 (6.7) Reference
HWE p =0.417 p =0.325
OR odds ratio, CI confidence interval, and HWE Hardy Weinberg equilibrium
*p < 0.05
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Considerably increased risk of ischemic events, in vari-
ous organs including brain has already been documented
in migraine [30]. Currently the exact mechanisms of
that relation between migraine and stroke are not under-
stood entirely. Distinct mechanisms were proposed for
migraine-related ischemia that occurs either during the
attack or attack-free periods. Additionally, it is not clear
yet if stroke is a consequence of migraine or both of the
conditions occur due to another shared pathological
course. In this case, a genetic link may be responsible
for influencing the course and variability of the conse-
quences of migraine [31]. Nevertheless, endothelial dys-
function was proposed as one of the main paths in this
association [32, 33].
U-II is a vasoactive peptide with ubiquitous effects
in various human body tissues. It has been sugges-
ted to have endothelium-dependent vasodilator and
endothelium-independent vasoconstrictor effects, with its
net effect depending on the balance between these two in-
dividual effects [12]. Yet in general, U-II is known to have
a powerful vasoconstrictor effect.
As mentioned above, since U-II has dual effect on
endothelium through distinct pathways and we don’t
have data if it has an effect in migraine attacks or not,
the blood samples were obtained in the interictal phase
in all of the cases. Therefore, the significantly higher
levels of plasma U-II in the present study present only
the U-II status in the attack-free period that may be a
limitation of the present study. Understanding the ef-
fects of U-II on the attacks is yet to be waiting for fur-
ther investigation. However, we believe that the stated
concerns about the dual effect of U-II should be taken
under consideration also in further research that aim to
investigate the plasma U-II effects in migraine attacks.
We found a significant positive relation between the
MIDAS scores and plasma U-II levels in the present
study. This finding may indicate that the severity of mi-
graine may be influenced by plasma U-II and in turn it
may have a bad effect in quality of life of the cases.
Many first-degree relatives of migraine patients have a
history of migraine, and twin studies showed that migraine
have a strong genetic component [3–5]. Genetic factors
may cause a tendency (predispose) to have migraine
attacks. Despite increasing number of studies suggesting a
role for genetic factors in the pathogenesis of migraine,
the responsible genes have not yet been determined. Des-
pite, neuronal vascular event chains triggered by endogen-
ous and/or exogenous factors in people with a genetic
predisposition, it is now believed that neuronal dysfunc-
tion is the possible primary reason in the pathophysiology
of the disease and vasodilation and vasoconstriction
phases are probably epiphenomena [34, 35].
Table 4 Haplotype distributions of UTS2 gene polymorphisms
in migraine patients and controls
Site 1 Site 2 Case (freq) Control (freq) p Odds Ratio [95 %CI]
M N 24.99 (0.067) 18.45 (0.054) 0.468 1.257 [0.676–2.338]
M S 119.01 (0.320) 110.55 (0.323) 0.891 0.978 [0.714–1.340]
T N 0.01 (0.000)a 1.55 (0.005)a - -
T S 227.99 (0.613) 211.45 (0.618) 0.822 0.966 [0.714–1.307]
aFrequencies < 0.03 were ignored in the analysis
Fig. 3 The relationship between plasma U-II protein level and Thr21Met polymorphism in patients
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Non-familial migraines can be considered as polygenic
when the diversity of both the number and severity of
attacks and the duration of the attacks are considered.
Various genes were supposed to be involved in migraine
pathophysiology. Our results indicate that a significant
association exists between the T21M polymorphism and
migraine. The T21M genotype patients were 1.63 times
more likely to become migraine than patients with the
T21T genotype in the present study. Amino acid change
upon Thr21Met polymorphism may affect protein fold-
ing efficiency or structure. By this way, differently folded
protein may be exposed to protein degradation processes
more or less than natively folded protein. Also, some
amino acid sequences form signal for degradation. With
this amino acid change, degradation signal may be cre-
ated and this causes U-II level to decrease. Moreover,
newly formed Met codon on mRNA may provide poten-
tial translation starting point for ribosome, although it is
a low probability. So, this causes a truncated U-II pro-
tein product. All these possibilities may explain U-II
level changes upon Thr21Met variant presence. Also, we
revealed that the plasma U-II levels tended to be higher
in cases with Thr21Met polymorphism as shown in
Fig. 3. However the difference couldn’t reach a statisti-
cally significant level.
Several publications have indicated a possible relation-
ship between UTS2 gene polymorphisms and hyperten-
sion, diabetes mellitus, Behçet’s disease, and systemic
sclerosis [17, 36–38]. Recently, genome-wide studies have
provided new insights for genes associated with migraine
disease (the ion channel gene, TRPM8, FHL5, ASTN2,
and LRP1 [39] but UTS2 gene was not one of them. Since,
we believe that it is worthy to evaluate this vasoactive pep-
tide in migraine pathophysiology since vascular changes
predominantly take place in migraine cases in both attack
and attack-free periods.
Conclusion
Our study suggests that U-II may play a role in migraine
pathogenesis, also Thr21Met polymorphism was associ-
ated with the risk of migraine disease. Further studies
are needed for considering the role of U-II in migraine
pathophysiology and for deciding if UTS2 gene may be a
novel candidate gene in migraine cases.
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